Press release - Novo Nordisk A/S

Novo Nordisk opens new insulin formulation and filling
facility in Russia
Moscow, Russia, 10 April 2015 – Today, Novo Nordisk opens a new manufacturing
facility in Russia for formulation and filling of modern insulin for the treatment of
diabetes. The production will cover both Penfill® cartridges and FlexPen® prefilled insulin
injection pens for the Russian market.
The new facility will be operating in accordance with current Good Manufacturing
Practices (GMP), and is located in Technopark Grabtsevo in the Kaluga region of Russia.
“The manufacturing facility in Kaluga is a sign of our long-term commitment to people
with diabetes in Russia, where close to 10 million people have the disease according to
local studies. With our investment in local manufacturing, we ensure availability of highquality modern insulins to the people with diabetes in Russia who rely on our products
every day,” said Lars Rebien Sørensen, CEO of Novo Nordisk.
This is the first and only greenfield facility for the manufacturing of modern insulin in
Russia. Environmental targets for CO² emission, water consumption and use of energy
have been established. With the construction of the new facility, Novo Nordisk has so far
created around 150 new jobs.
“The opening of Novo Nordisk manufacturing facility in Kaluga is a sign of confidence in
our region, as well as an important stage in the formation of a pharmaceutical cluster in
Kaluga. I am convinced that the new facility will have a significant impact on improving
the quality of life for people with diabetes in Kaluga as well as in the rest of Russia,” said
Kaluga Region Governor, Anatoly Artamonov.
Novo Nordisk also has production sites in Denmark, Brazil, China, France and the US.
Headquartered in Denmark, Novo Nordisk is a global healthcare company with more than 90 years of
innovation and leadership in diabetes care. The company also has leading positions within haemophilia
care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately
41,500 employees in 75 countries, and markets its products in more than 180 countries. For more
information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube
Novo Nordisk A/S
Corporate Communications
Novo Allé
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
Page 2 of 2
Further information:
Media:
Katrine Sperling
+45 3079 6718
krsp@novonordisk.com
Investors:
Kasper Roseeuw Poulsen
+45 3079 4303
krop@novonordisk.com
Daniel Bohsen
+45 3079 6376
dabo@novonordisk.com
Melanie Raouzeos
+45 3075 3479
mrz@novonordisk.com
Frank Daniel Mersebach (US)
+1 609 235 8567
fdni@novonordisk.com
Novo Nordisk A/S
Corporate Communications
Novo Allé
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
Internet:
www.novonordisk.com
CVR no:
24 25 67 90